Why Bristol-Myers Squibb (BMY) is on investors’ radar
Bristol-Myers Squibb (BMY) is drawing attention after recent share price moves, with the stock showing a mix of short term pressure and longer term resilience that invites a closer look at its fundamentals.
See our latest analysis for Bristol-Myers Squibb.
At a share price of US$58.54, Bristol-Myers Squibb has seen a 1 day share price decline of about 1.5%, alongside a 9.5% year to date share price return and a 12.6% five year total shareholder return, which together indicate that momentum has been rebuilding over time.
If you are reassessing healthcare exposure after BMY’s recent moves, it can be helpful to compare it with other pharma focused opportunities using our 34 healthcare AI stocks
With an intrinsic value estimate suggesting roughly a 51% discount and the share price sitting below the average analyst target, Bristol-Myers Squibb appears inexpensive on paper. However, is this a genuine entry point, or is the market already pricing in what comes next?
Most Popular Narrative: 9.9% Undervalued
According to Evangelos, the widely followed narrative pegs Bristol-Myers Squibb’s fair value at about $65 per share, compared to the recent close at $58.54, framing the current gap as a discount that hinges on earnings power and cash flow durability.
Full-Year 2024 Highlights:
• Total Revenues: $48.3 billion, a 7% increase from 2023.
• GAAP Loss Per Share: $(4.41), compared to earnings of $3.86 in 2023.
• Non-GAAP EPS: $1.15, a significant decrease from $7.51 in 2023.
• Growth Portfolio Revenues: $22.6 billion, a 17% increase, indicating robust performance of newer products.
The fair value story here leans heavily on a growing newer drug portfolio, margin rebuilding and a future earnings profile that looks very different from the latest GAAP loss.
Result: Fair Value of $65 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh risks such as pressure on non GAAP EPS and any setback to new product uptake that could challenge the current undervalued story.
Find out about the key risks to this Bristol-Myers Squibb narrative.
Next Steps
If this mix of optimism and caution around Bristol-Myers Squibb feels familiar, use the full dataset to pressure test the narrative for yourself and move quickly to form a clear view by checking the 3 key rewards and 2 important warning signs.
Ready for more investment ideas?
If BMY has sharpened your interest, do not stop here. Broaden your watchlist with focused stock ideas that match different goals and risk levels.
- Target potential mispricings by scanning companies that currently look attractively valued using our 62 high quality undervalued stocks.
- Strengthen your income stream by checking businesses that combine higher yields with staying power via the 12 dividend fortresses.
- Reduce portfolio stress by focusing on companies that our models flag for resilience with the 64 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com